单次立体定向体部放疗:COVID-19疫情期间及之后的治疗范式?
本文通过PubMed检索综述单次立体定向体部放疗(SBRT)的临床证据。周围型早期非小细胞肺癌有随机数据支持,疫情期间获欧洲放射肿瘤学会-美国放射肿瘤学会指南推荐;肾细胞癌、肝转移和肾上腺转移结果有前景但证据有限;前列腺癌数据不成熟,胰腺癌显示晚期毒性增加。结论:疫情期间应强烈考虑对周围型早期非小细胞肺癌采用单次SBRT,其他情况仍首选多次SBRT。
要点
- 周围型早期非小细胞肺癌单次SBRT有随机数据支持,疫情期间获指南推荐
- 肾细胞癌、肝转移和肾上腺转移的单次SBRT结果有前景但证据有限
- 前列腺癌数据不成熟,胰腺癌单次SBRT显示晚期毒性增加
核心结论
- COVID-19疫情期间应强烈考虑对周围型早期非小细胞肺癌采用单次SBRT,以减少SARS-CoV-2传播的潜在严重后果。
- 其他原发或寡转移癌症的单次SBRT虽有前景,但仍需前瞻性评估长期疗效和安全性,应首选多次SBRT。
研究设计与样本
- 通过PubMed检索英文发表的单次SBRT相关文章,对描述原发颅外癌症和寡转移性椎外疾病临床结局的文章进行批判性综述。
主要发现
- 周围型早期非小细胞肺癌的单次SBRT有随机数据支持,并获欧洲放射肿瘤学会-美国放射肿瘤学会实践指南在COVID-19疫情期间强烈推荐。
- 支持单次方案的前瞻性和回顾性研究有限,但肾细胞癌、肝转移和肾上腺转移的结果有前景。
- 前列腺癌原发治疗数据不成熟,胰腺癌原发治疗显示晚期毒性增加。
- 单次SBRT已确立用于骨转移治疗,但用于其他颅外部位不常见。
关键数值与推荐
- 周围型早期非小细胞肺癌:单次SBRT获随机数据支持及欧洲放射肿瘤学会-美国放射肿瘤学会指南推荐。
- 肾细胞癌、肝转移、肾上腺转移:前瞻性和回顾性研究有限,结果有前景。
- 前列腺癌:数据不成熟;胰腺癌:显示晚期毒性增加。
临床怎么用
- COVID-19疫情期间,对周围型早期非小细胞肺癌应强烈考虑单次SBRT以降低传播风险。
- 其他原发或寡转移癌症的 definitive 治疗,因需进一步前瞻性评估长期疗效和安全性,应首选多次SBRT。
- 单次SBRT已确立用于骨转移,但用于其他颅外部位需谨慎评估证据。
局限性
- 支持单次SBRT用于非小细胞肺癌以外部位的前瞻性和回顾性研究有限。
- 前列腺癌数据不成熟,胰腺癌显示晚期毒性增加,长期疗效和安全性需进一步前瞻性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Owing to the coronavirus disease 2019 (COVID-19) pandemic, radiation oncology departments have adopted various strategies to deliver radiation therapy safely and efficiently while minimizing the risk of severe acute respiratory syndrome coronavirus-2 transmission among patients and health care providers. One practical strategy is to deliver stereotactic body radiation therapy (SBRT) in a single fraction, which has been well established for treating bone metastases, although it has been infrequently used for other extracranial sites. METHODS AND MATERIALS: A PubMed search of published articles in English related to single-fraction SBRT was performed. A critical review was performed of the articles that described clinical outcomes of single-fraction SBRT for treatment of primary extracranial cancers and oligometastatic extraspinal disease. RESULTS: Single-fraction SBRT for peripheral early-stage non-small cell lung cancer is supported by randomized data and is strongly endorsed during the COVID-19 pandemic by the European Society for Radiotherapy and Oncology-American Society for Radiation Oncology practice guidelines. Prospective and retrospective studies supporting a single-fraction regimen are limited, although outcomes are promising for renal cell carcinoma, liver metastases, and adrenal metastases. Data are immature for primary prostate cancer and demonstrate excess late toxicity in primary pancreatic cancer. CONCLUSIONS: Single-fraction SBRT should be strongly considered for peripheral early-stage non-small cell lung cancer during the COVID-19 pandemic to mitigate the potentially severe consequences of severe acute respiratory syndrome coronavirus-2 transmission. Although single-fraction SBRT is promising for the definitive treatment of other primary or oligometastatic cancers, multi-fraction SBRT should be the preferred regimen owing to the need for additional prospective evaluation to determine long-term efficacy and safety.
引用
- Ng SSW, Ning MS, Lee P, et al. Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond? Adv Radiat Oncol. 2020. PMID: 32775790. doi:10.1016/j.adro.2020.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。